Anandhitha Arasu

Immunotherapy Effects of Meningioma

Started Oct. 20, 2023

Abstract or project description

Immunotherapy faces numerous challenges when treating brain and spinal tumors. The main challenge is eliminating the cancer cells without damaging the brain and spine. The review also focuses on how immunotherapy can only delay brain and spinal cancers but not fully treat them. This paper analyzes Pembrolizumab (Keytruda), a humanized monoclonal antibody which recent studies show as a promising option regarding meningioma and immunotherapy. Two clinical trials are further analyzed connecting immunotherapy and meningioma, with one still ongoing trial.